InMed Pharmaceuticals Inc. (INM): Nasdaq/NYSE listing notice — InMed granted 180-day Nasdaq extension to regain minimum bid compliance

InMed Pharmaceuticals Inc.

Nasdaq extended compliance period to Sept 16, 2024 to meet $1.00 minimum bid price.
Must achieve closing bid of $1.00 or more for 10 consecutive business days.
Previously notified of non-compliance on Sept 19, 2023; original deadline was March 18, 2024.
Company may consider a reverse stock split if needed; no immediate effect on trading.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

InMed Pharmaceuticals Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 19, 2024, the Company received written notification (the “Current Notification”) from the Listing Qualifications Department of Nasdaq that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the “Extended Compliance Period”), to regain compliance with the Minimum Bid Price Rule. Nasdaq’s determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

InMed Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-024305

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.